The COVID-19 vaccine from the US laboratory Pfizer and its German partner BioNTech is getting closer to approval and distribution. Already on the first of this month, they announced that they had requested EU regulatory approval for their vaccine, raising hopes that the first vaccinations could be administered in December.
Both companies announced that they had submitted an application to the European Medicines Agency (EMA) "for Conditional Marketing Authorization (AMC)" of their vaccine, after tests showed it to be 95 percent effective against the new coronavirus. If approved, the BNT162b2 vaccine could potentially be launched "in . . .
